A critical overview on ticagrelor in acute coronary syndromes

Antonino Maria Tommaso Buffon, E. P. Navarese, M. Kozinski, K. Obonska, M. Rychter, V. Kunadian, D. Austin, S. De Servi, A. Sukiennik, J. Kubica

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.
Original languageEnglish
Pages (from-to)105-115
Number of pages11
JournalQJM-AN INTERNATIONAL JOURNAL OF MEDICINE
Volume106
DOIs
Publication statusPublished - 2013

Keywords

  • Acute Coronary Syndrome
  • Adenosine
  • Aspirin
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Platelet Aggregation Inhibitors
  • Purinergic P2 Receptor Antagonists
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Ticlopidine
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'A critical overview on ticagrelor in acute coronary syndromes'. Together they form a unique fingerprint.

Cite this